Research Imaging Centre, Centre for Addiction and Mental Health, 250 College Street, Toronto, Ontario, M5T 1R8, Canada; Department of Psychiatry, University of Toronto, 250 College Street, Toronto, Ontario, M5T 1R8, Canada.
Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, 250 College Street, Toronto, Ontario, M5T 1R8, Canada; Molecular and Cellular Cognition Lab, German Center for Neurodegenerative Diseases(DZNE), Bonn, Germany.
Exp Eye Res. 2018 Oct;175:32-41. doi: 10.1016/j.exer.2018.06.006. Epub 2018 Jun 5.
Dopamine D receptors (DR) are expressed in the human retina and play an important role in the modulation of neural responses to light-adaptation. However, it is unknown whether dopamine D receptors (DR) are expressed in the human retina. Using positron emission tomography (PET), we have observed significant uptake of the DR-preferring agonist radiotracer [C]-(+)-PHNO into the retina of humans in vivo. This led us to examine whether [C]-(+)-PHNO binding in the retina was quantifiable using reference tissue methods and if DR are expressed in human post-mortem retinal tissue. [C]-(+)-PHNO data from 49 healthy controls (mean age: 39.96 ± 14.36; 16 female) and 12 antipsychotic-naïve patients with schizophrenia (mean age: 25.75 ± 6.25; 4 female) were analyzed. We observed no differences in [C]-(+)-PHNO binding in the retina between first-episode, drug-naïve patients with schizophrenia and healthy controls. Post-mortem retinal tissues from four healthy persons (mean age: 59.75 ± 9.11; 2 female) and four patients with schizophrenia (mean age: 54 ± 17.11; 2 female) were analyzed using a targeted mass spectrometry technique: parallel reaction monitoring (PRM) analysis. Using targeted mass spectrometry, we confirmed that DR are expressed in human retinal tissue ex vivo. Notably, there was far greater expression of DR relative to DR in the healthy human retina (∼12:1). Moreover, PRM analysis revealed reduced DR, but not DR, expression in the retinas of non-first episode patients with schizophrenia compared to healthy controls. We confirm that DR are expressed in the human retina. Future studies are needed to determine what proportion of the [C]-(+)-PHNO signal in the human retina in vivo is due to binding to DR versus DR. Knowledge that both DR and DR are expressed in the human retina, and potentially quantifiable in vivo using [C]-(+)-PHNO, poses new research avenues for better understanding the role of retinal dopamine in human vision. This work may have important implications for elucidating pathophysiological and antipsychotic induced visual deficits in schizophrenia.
多巴胺 D 受体 (DR) 在人视网膜中表达,并在光适应调节神经反应中发挥重要作用。然而,尚不清楚多巴胺 D 受体 (DR) 是否在人视网膜中表达。我们使用正电子发射断层扫描 (PET),观察到 DR 优先激动剂放射性示踪剂 [C]-(+)-PHNO 在人体内视网膜的显著摄取。这促使我们检查是否可以使用参照组织方法对视网膜中的 [C]-(+)-PHNO 结合进行定量,以及 DR 是否在人死后的视网膜组织中表达。对 49 名健康对照者(平均年龄:39.96±14.36;16 名女性)和 12 名未经抗精神病药物治疗的精神分裂症患者(平均年龄:25.75±6.25;4 名女性)的 [C]-(+)-PHNO 数据进行了分析。我们观察到,首发、未经药物治疗的精神分裂症患者与健康对照者的视网膜中 [C]-(+)-PHNO 结合无差异。对 4 名健康人(平均年龄:59.75±9.11;2 名女性)和 4 名精神分裂症患者(平均年龄:54±17.11;2 名女性)的死后视网膜组织进行了靶向质谱技术(平行反应监测 [PRM] 分析)。使用靶向质谱,我们确认 DR 在人视网膜组织中表达。值得注意的是,与健康人视网膜相比,DR 在人视网膜中的表达量远远高于 DR(约为 12:1)。此外,PRM 分析显示,与健康对照组相比,非首发精神分裂症患者的视网膜中 DR 表达减少,但 DR 表达未减少。我们确认 DR 在人视网膜中表达。需要进一步的研究来确定体内 [C]-(+)-PHNO 信号在人视网膜中的多少部分归因于与 DR 结合,多少部分归因于 DR。已知 DR 和 DR 均在人视网膜中表达,并且可以使用 [C]-(+)-PHNO 进行体内定量,这为更好地理解视网膜多巴胺在人视觉中的作用开辟了新的研究途径。这项工作可能对阐明精神分裂症中的病理生理和抗精神病药物引起的视觉缺陷具有重要意义。